Literature DB >> 8101214

Suppression by dynorphin A and [des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice.

A E Takemori1, H H Loh, N M Lee.   

Abstract

Previously, we demonstrated that the expression of opiate withdrawal and antinociceptive tolerance can be suppressed by dynorphin (dyn) A-(1-13) in morphine-dependent mice. In this study, it was shown that the normal, endogenous dyn, dyn A-(1-17) also possessed this suppressive property. While using the nonopioid dyn analog, [des-Tyr1]dyn A [dyn A-(2-17)] as a negative control, we discovered unexpectedly that this peptide fragment also suppressed naloxone-induced withdrawal and the expression of morphine tolerance in morphine-dependent mice. Thus, an extensive structure activity relationship was studied using 11 peptide fragments. It was determined that the amino acid sequence of dyn A was required for the suppressive activity because dyn B and alpha-neoendorphin both failed to suppress naloxone-precipitated withdrawal jumping. Of the [des-Tyr1]dyn fragments, the minimal amino acid sequence required to suppress naloxone-induced withdrawal was determined to be dyn A-(2-8), containing the sequence G-G-F-L-R-R-I.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101214

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Exposure to cocaine alters dynorphin-mediated regulation of excitatory synaptic transmission in nucleus accumbens neurons.

Authors:  Ping Mu; Peter A Neumann; Jaak Panksepp; Oliver M Schlüter; Yan Dong
Journal:  Biol Psychiatry       Date:  2010-10-27       Impact factor: 13.382

3.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Metabolism of dynorphin A1-13 in human CSF.

Authors:  S Müller; B L Grundy; G Hochhaus
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

5.  Dynorphin peptides: antagonists of melanocortin receptors.

Authors:  J M Quillan; W Sadée
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse.

Authors:  Andrew C H Chen; K Steven LaForge; Ann Ho; Pauline F McHugh; Scott Kellogg; Kathy Bell; Rosemary P Schluger; Suzanne M Leal; Mary Jeanne Kreek
Journal:  Am J Med Genet       Date:  2002-05-08

7.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  Dynorphin peptides differentially regulate the human kappa opioid receptor.

Authors:  Yong Chen; Chongguang Chen; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2007-01-20       Impact factor: 5.037

Review 9.  Feeding, drug abuse, and the sensitization of reward by metabolic need.

Authors:  K D Carr
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

10.  Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats.

Authors:  Suliman I Al-Fayoumi; Boglarka Brugos; Vikram Arya; Esther Mulder; Barbel Eppler; Andre P Mauderli; Günther Hochhaus
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.